Literature DB >> 8933045

Rocky Flats Beryllium Health Surveillance.

A W Stange1, F J Furman, D E Hilmas.   

Abstract

The Rocky Flats Beryllium Health Surveillance Program (BHSP), initiated in June 1991, was designed to provide medical surveillance for current and former employees exposed to beryllium. The BHSP identifies individuals who have developed beryllium sensitivity using the beryllium lymphocyte proliferation test (BeLPT). A detailed medical evaluation to determine the prevalence of chronic beryllium disease (CBD) is offered to individuals identified as beryllium sensitized or to those who have chest X-ray changes suggestive of CBD. The BHSP has identified 27 cases of CBD and another 74 cases of beryllium sensitization out of 4268 individuals tested. The distribution of BeLPT values for normal, sensitized, and CBD-identified individuals is described. Based on the information collected during the first 3 1/3 years of the BHSP, the BeLPT is the most effective means for the early identification of beryllium-sensitized individuals and to identify individuals who may have CBD. The need for BeLPT retesting is demonstrated through the identification of beryllium sensitization in individuals who previously tested normal. Posterior/anterior chest X-rays were not effective in the identification of CBD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8933045      PMCID: PMC1469682          DOI: 10.1289/ehp.96104s5981

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  10 in total

1.  The study of observer variation in the radiological classification of pneumoconiosis.

Authors:  J W FAY; J R ASHFORD
Journal:  Br J Ind Med       Date:  1960-10

2.  Screening blood test identifies subclinical beryllium disease.

Authors:  K Kreiss; L S Newman; M M Mroz; P A Campbell
Journal:  J Occup Med       Date:  1989-07

3.  A study of the immunologic aspects of chronic berylliosis.

Authors:  S D Deodhar; B Barna; H S Van Ordstrand
Journal:  Chest       Date:  1973-03       Impact factor: 9.410

4.  In vitro studies on granulomatous hypersensitivity to beryllium.

Authors:  J M Hanifin; W L Epstein; M J Cline
Journal:  J Invest Dermatol       Date:  1970-10       Impact factor: 8.551

Review 5.  Chronic beryllium disease--from the workplace to cellular immunology, molecular immunogenetics, and back.

Authors:  K Kreiss; F Miller; L S Newman; E A Ojo-Amaize; M D Rossman; C Saltini
Journal:  Clin Immunol Immunopathol       Date:  1994-05

6.  Value of beryllium lymphocyte transformation tests in chronic beryllium disease and in potentially exposed workers.

Authors:  W J Williams; W R Williams
Journal:  Thorax       Date:  1983-01       Impact factor: 9.139

7.  HLA-DPB1 glutamate 69: a genetic marker of beryllium disease.

Authors:  L Richeldi; R Sorrentino; C Saltini
Journal:  Science       Date:  1993-10-08       Impact factor: 47.728

8.  Epidemiology of beryllium sensitization and disease in nuclear workers.

Authors:  K Kreiss; M M Mroz; B Zhen; J W Martyny; L S Newman
Journal:  Am Rev Respir Dis       Date:  1993-10

9.  Early pulmonary physiologic abnormalities in beryllium disease.

Authors:  G P Pappas; L S Newman
Journal:  Am Rev Respir Dis       Date:  1993-09

10.  Proliferative response of bronchoalveolar lymphocytes to beryllium. A test for chronic beryllium disease.

Authors:  M D Rossman; J A Kern; J A Elias; M R Cullen; P E Epstein; O P Preuss; T N Markham; R P Daniele
Journal:  Ann Intern Med       Date:  1988-05       Impact factor: 25.391

  10 in total
  7 in total

1.  Beryllium's public relations problem: protecting workers when there is no safe exposure level.

Authors:  David Michaels; Celeste Monforton
Journal:  Public Health Rep       Date:  2008 Jan-Feb       Impact factor: 2.792

2.  Progression from beryllium exposure to chronic beryllium disease: an analytic model.

Authors:  Philip Harber; Siddharth Bansal; John Balmes
Journal:  Environ Health Perspect       Date:  2009-02-27       Impact factor: 9.031

3.  Quantification and micron-scale imaging of spatial distribution of trace beryllium in shrapnel fragments and metallurgic samples with correlative fluorescence detection method and secondary ion mass spectrometry (SIMS).

Authors:  J L Abraham; S Chandra; A Agrawal
Journal:  J Microsc       Date:  2014-08-22       Impact factor: 1.758

4.  Chronic beryllium disease, HLA-DPB1, and the DP peptide binding groove.

Authors:  Lori J Silveira; Erin C McCanlies; Tasha E Fingerlin; Michael V Van Dyke; Margaret M Mroz; Matthew Strand; Andrew P Fontenot; Natalie Bowerman; Dana M Dabelea; Christine R Schuler; Ainsley Weston; Lisa A Maier
Journal:  J Immunol       Date:  2012-09-12       Impact factor: 5.422

5.  Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry.

Authors:  Michael V Van Dyke; John W Martyny; Margaret M Mroz; Lori J Silveira; Matt Strand; Donna L Cragle; William G Tankersley; Susan M Wells; Lee S Newman; Lisa A Maier
Journal:  Occup Environ Med       Date:  2011-04-02       Impact factor: 4.402

6.  Interpreting borderline BeLPT results.

Authors:  D C Middleton; A S Mayer; M D Lewin; M M Mroz; L A Maier
Journal:  Am J Ind Med       Date:  2010-10-18       Impact factor: 2.214

7.  Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers.

Authors:  Mike V Van Dyke; John W Martyny; Margaret M Mroz; Lori J Silveira; Matt Strand; Tasha E Fingerlin; Hiroe Sato; Lee S Newman; Lisa A Maier
Journal:  Am J Respir Crit Care Med       Date:  2011-03-11       Impact factor: 21.405

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.